Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.[3]
It was patented in 1996 and approved for medical use in 2002.[4]
^"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^"Merck & Co., Inc. (Jobs) Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)". BioSpace. Retrieved 15 October 2023.
^Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 978-3-527-60749-5.
Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide...
gastrointestinal tract. Selectivity for COX-2 is the main feature of celecoxib, etoricoxib, and other members of this drug class. Because COX-2 is usually specific...
University. At Merck, she became the chief statistician on the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme, a large international...
versions in general). These drugs (such as rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared with NSAIDs, but cause...
substituent (SO2NH2) in para-position on one of the aryl rings while etoricoxib and rofecoxib have a methylsulfone (SO2CH3). The oxidation state on the...
there was no significant difference between NSAIDs. It was concluded that etoricoxib was more effective in reducing pain of AS, however due to small studies...
gastrointestinal bleeding. Coxibs (COX-2 inhibitors) e.g. celecoxib or etoricoxib, are associated with a statistically significant 50 to 66% relative risk...
chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma". Biomedical Chromatography. 19 (2): 113–118...
Global Information
